title: Nonalcoholic fatty liver disease and HIV infection.
abstract: Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome that includes a range of disorders associated with fatty liver from steatosis to cirrhosis and hepatocellular carcinoma, defined by the presence of liver fat accumulation exceeding 5% of hepatocytes in the absence of other causes of liver disease such as alcohol consumption, viral hepatitis, or any other specific etiology. Half the patients with human immunodeficiency virus (HIV) who undergo additional testing for unexplained liver test abnormalities may suffer from NAFLD, which is the hepatic manifestation of the metabolic syndrome. In HIV-infected patients, NAFLD can result from the HIV itself, highly active antiretroviral therapy (HAART), and/or lipodystrophy. Evaluation of the liver impact of NAFLD remains mainly based on liver biopsy, but numerous noninvasive procedures are under evaluation. In HIV/hepatitis C virus (HCV-) coinfected patients, steatosis seems more frequent and severe by comparison with HCV-monoinfected patients, and is associated with significant liver fibrosis, which may contribute to the more rapid progression of liver disease. First-line treatment of NAFLD is mainly based on the adequate management of the metabolic syndrome, including lifestyle changes. Specific therapeutic approaches are under investigation.
authors: Unité d'Hépatologie, Hôpital Cochin Saint Vincent de Paul, Université Paris Descartes, APHP, Paris, France.
authors: Anaïs
authors: A
authors: Vallet-Pichard
authors: Vincent
authors: V
authors: Mallet
authors: Stanislas
authors: S
authors: Pol
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D060085:Coinfection; D005234:Fatty Liver / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D006678:HIV; D015658:HIV Infections / Q000150:complications*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000209:etiology* / Q000517:prevention & control; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology* / Q000517:prevention & control; D024821:Metabolic Syndrome / Q000150:complications*; D015995:Prevalence